Low Cardiac OutputNCT02599376
Comparative Study of Haemodynamic Changes After Spinal Anaesthesia in Non-obese and Pregnant Women
A study testing LiDCOrapid in people with Low Cardiac Output, run by University of Aberdeen at 1 site in United Kingdom.
Trial summary
Obesity has become one of the most common risk factors in obstetric practice with serious anaesthetic implications. Obese pregnants have limited physiological reserves and cardiovascular co- morbidities when compared to non-obese pregnant women. Read more about this study
- Who is it for?
- Any age, women onlyHealthy volunteers can take part
- Conditions the study is for
- Low Cardiac Output
- What is being tested?
- LiDCOrapid
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- Dec 2014to Aug 2016
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- Women only
- Healthy volunteers accepted
- Child, Adult, Older adult
Who may be able to join
- Pregnant patients with BMI of less than 30 undergoing elective CS.
- Obese pregnant patients with BMI of more than 35 undergoing elective CS
Who cannot join
- Patients with other comorbidities like pre-eclampsia, eclampsia, essential hypertension, respiratory disease and compromised renal function.
- Patients on long-term medication.
- Patients having CS under epidural.
- Patients having general anaesthesia.
- Patients on antihypertensive medication.
- Patients with BMI of 31-34.
- Patients less than 36 weeks of gestation
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
Aberdeen Maternity Hospital
Aberdeen, Aberdeen, AB25 2ZN
About this study
Obesity has become one of the most common risk factors in obstetric practice with serious anaesthetic implications. Obese pregnants have limited physiological reserves and cardiovascular co- morbidities when compared to non-obese pregnant women. Spinal anaesthesia is the anaesthetic technique of choice for caesarean section. The haemodynamic changes associated with spinal anaesthesia pose the greatest hazard to the mother and the foetus and are exaggerated in obese pregnant women. However differences in the changes in haemodynamic variables such as cardiac output (CO), stroke volume (SV) and systemic vascular resistance (SVR) between obese and non-obese pregnant women having caesarean section (CS) under spinal anaesthesia have not been studied before. This study compares the haemodynamic changes after spinal anaesthesia for CS in non-obese and obese parturients in a single centre, prospective case control study, using LiDCOrapidV2. This LiDCOrapidV2 device is a noninvasive method of measuring haemodynamic variables. It is a single centre, prospective, case control study. The primary outcome compares the differences and variability in CO, SV and SVR between obese and non-obese parturients. The secondary outcomes include comparison of the correlation between changes in blood pressure (BP) and CO in each patient and the difference in BP between conventional intermittent oscillometric device and continuous LiDCORapidV2in each patient with a view to assess the need for measurement of cardiac output in obstetric anaesthesia
Read the detailed description
Pregnancy is a state of physiological alteration as a result of increased oxygen demand and involves significant haemodynamic changes including sustained rises in cardiac output (CO) (by up to 30- 60%) and stroke volume (SV) (up to 30%) by virtue of increase in the blood volume This is associated with decrease in the systemic vascular resistance (SVR) and enhanced myocardial performance. When pregnancy is associated with obesity the cardiovascular system is further stressed. Obese pregnant women with a body mass index (BMI) more than 35kg/m2 pose significant health issue and are at risk for anaesthesia related maternal mortality. Several cases of sudden cardiac arrests of unexplained cause in obese pregnants have been reported. Obesity induced pathological changes have profound effects on cardiac endothelial and vascular function. Thus in pregnancy, obesity leads to further increase in blood volume and cardiac output proportionate to the amount of fat thus causing further volume overload of the heart. A study conducted with transthoracic echo showed a mean increase of around 550mls in cardiac output between obese and non-obese parturients in the third trimester. In contrast to the decrease in SVR that occurs in normal pregnancy, obesity by itself is associated with increased SVR by virtue of the increased sympathetic activity due to the effects of hormones including leptin, insulin and inflammatory mediators. This causes an increase in afterload 6, 8 thus offsetting the advantage of reduced afterload of normal pregnancy affecting the CO further. This combination of volume and pressure overload leads to systolic dysfunction. Furthermore the increase in heart rate of pregnancy in line with elevated cardiac output will decrease the diastolic interval and time for myocardial perfusion causing diastolic dysfunction. Thus obese pregnant patients may present with a systolic, diastolic or both systolic and diastolic dysfunction of the left ventricle. Associated obstructive sleep apneoa (OSA) and pulmonary hypertension may lead to right ventricular failure. These changes are further compromised in the third trimester due to aortocaval compression thus reducing cardiac output and placental perfusion. The large abdominal panniculus in obesity will further add to the uterine and vascular compression. It is thus evident that obese parturient women pose an increase in risk for cardiovascular compromise. As obesity is considered a global health care problem especially in women, anaesthetists are increasingly faced with the care of this high risk group of patients.9However there is paucity of evidence to quantify this cardiovascular compromise on obese pregnant women and guide provision of best care.
Regional anaesthesia has been the preferred technique of anaesthesia, especially in obese pregnant patients. Induction of spinal anaesthesia will cause profound haemodynamic changes that represent the greatest hazard to the mother and the foetus. Evidence suggests these haemodynamic changes are common after spinal anaesthesia and results in hypotension causing unconsciousness, maternal nausea and vomiting, dizziness including deleterious effects on the foetus like neonatal acidaemia and lower APGAR score. However because of the changes in peripheral vascular resistance, changes in maternal arterial pressure do not necessarily reflect changes in maternal cardiac output. These changes in cardiac output and associated oxygen delivery pose the greatest risk to the foetus.
A recent review of cardiovascular alterations in the parturient undergoing caesarean delivery with neuraxial anaesthesia showed that induction of spinal anaesthesia will lead to decrease in CO by 10-35% as measured by various invasive techniques. Although the patho-physiology of pregnancy and obesity and echocardiography findings gives us an understanding that these patients are more prone for severe hypotension and cardiovascular compromise the extent of alteration of haemodynamic variables in obese pregnant patients during spinal anaesthesia has not been studied previously. Our primary aim therefore is to investigate the haemodynamic alterations in obese parturient during spinal anaesthesia and compare it with those in non-obese parturient.
Traditionally clinicians and researchers have used heart rate (HR)and BP as surrogate markers of cardiac output during spinal anaesthesia. Managing maternal BP was considered as safe optimization of foetal wellbeing. Recent publications have emphasized that keeping BP at baseline is not an optimal strategy and maintaining CO is superior in maintaining uterine blood flow. In addition the correlation of the foetal compromise in the form of umbilical artery pH and umbilical artery pulsatality index was better related to SV and CO than BP and heart rate. 19 Thus measurement of CO is considered a better approach than BP in optimising oxygen delivery to the foetus.
Although pulmonary artery catheterization is a gold standard for measuring cardiac output it is not desirable to use routinely because of its invasiveness, patient compliance and its potential complications. Minimally invasive CO monitors like LiDCO plus has been validated and successfully used for this purpose, but still require an arterial line and is complex for routine use.
LiDCOrapidV2(LiDCO Group plc, LiDCO Limited, United Kingdom), incorporates the CNAPTM (continuous noninvasive arterial pressure) module that derives CO, SV, and SVR from a continuous noninvasive arterial waveform and analysed by the PulseCOTM algorithm avoiding invasive blood pressure measurements. This study studies the clinical application of the LIDCOrapidV2 and compares the haemodynamic variables in obese and non-obese pregnant women having CS under spinal anaesthesia.
- Conditions
- Low Cardiac Output
- Being tested
- LiDCOrapid
- Medical subject headings
- Cardiac Output, Low
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
LiDCOrapidDevice
Cardiac output will be non invasively monitored by using 2 cuffs on fingers.
| Study group | Role | What they receive |
|---|---|---|
| BMI less than 30 | Active comparator | The drop in cardiac output after spinal anaesthesia for LSCS at various intervals with LiDCORapid Receives: Device: LiDCOrapid |
| BMI more than 40 | Experimental | The drop in cardiac output after spinal anaesthesia for LSCS at various intervals with LiDCORapid Receives: Device: LiDCOrapid |
What is being measured
The primary outcome is the main question the study is designed to answer.
Difference in the variation of cardiac output (CO) from baseline values between obese and non-obese parturients after spinal anaesthesia.
The change in cardiac output from baseline measured as milliliters/minute at predetermined intervals after spinal anaesthesia will be recorded in each group. The mean value of this change in each group will be compared for each recording and the difference in the change between the two groups will be reported.
Measured: 18 months
Secondary outcomes (1)
Mean difference in the amount of vasopressors infused in millilitres/hour between non-obese and obese pregnant women.
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Nov 2015 (estimated)
- Study startDec 2014
- Primary completionAug 2016
- Study completionAug 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Low Cardiac OutputStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Care provider
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Aberdeen
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Manisha Kumar, FRCA, Principal investigator, NHS Grampian
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02599376
- Sponsor's protocol ID
- 1/028/14
- Status last verified
- Sep 2016
- First submitted
- 15 Dec 2014
- Last updated
- 8 Sep 2016
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Sep 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparative Study of Haemodynamic Changes After Spinal Anaesthesia in Non-obese and Pregnant Women
- ClinicalTrials.gov ID
- NCT02599376
- Acronym / sponsor ID
- 1/028/14
- Conditions
- Low Cardiac Output
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 60 participants (actual)
- Lead sponsor
- University of AberdeenUniversity, hospital or other
- Study start
- Dec 2014
- Primary completion
- Aug 2016 (actual)
- Study completion
- Aug 2016 (actual)
- First posted
- 6 Nov 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Obesity has become one of the most common risk factors in obstetric practice with serious anaesthetic implications. Obese pregnants have limited physiological reserves and cardiovascular co- morbidities when compared to non-obese pregnant women. Spinal anaesthesia is the anaesthetic technique of choice for caesarean section. The haemodynamic changes associated with spinal anaesthesia pose the greatest hazard to the mother and the foetus and are exaggerated in obese pregnant women. However differences in the changes in haemodynamic variables such as cardiac output (CO), stroke volume (SV) and systemic vascular resistance (SVR) between obese and non-obese pregnant women having caesarean section (CS) under spinal anaesthesia have not been studied before. This study compares the haemodynamic changes after spinal anaesthesia for CS in non-obese and obese parturients in a single centre, prospective case control study, using LiDCOrapidV2. This LiDCOrapidV2 device is a noninvasive method of measuring haemodynamic variables. It is a single centre, prospective, case control study. The primary outcome compares the differences and variability in CO, SV and SVR between obese and non-obese parturients. The secondary outcomes include comparison of the correlation between changes in blood pressure (BP) and CO in each patient and the difference in BP between conventional intermittent oscillometric device and continuous LiDCORapidV2in each patient with a view to assess the need for measurement of cardiac output in obstetric anaesthesia
Detailed description
Pregnancy is a state of physiological alteration as a result of increased oxygen demand and involves significant haemodynamic changes including sustained rises in cardiac output (CO) (by up to 30- 60%) and stroke volume (SV) (up to 30%) by virtue of increase in the blood volume This is associated with decrease in the systemic vascular resistance (SVR) and enhanced myocardial performance. When pregnancy is associated with obesity the cardiovascular system is further stressed. Obese pregnant women with a body mass index (BMI) more than 35kg/m2 pose significant health issue and are at risk for anaesthesia related maternal mortality. Several cases of sudden cardiac arrests of unexplained cause in obese pregnants have been reported. Obesity induced pathological changes have profound effects on cardiac endothelial and vascular function. Thus in pregnancy, obesity leads to further increase in blood volume and cardiac output proportionate to the amount of fat thus causing further volume overload of the heart. A study conducted with transthoracic echo showed a mean increase of around 550mls in cardiac output between obese and non-obese parturients in the third trimester. In contrast to the decrease in SVR that occurs in normal pregnancy, obesity by itself is associated with increased SVR by virtue of the increased sympathetic activity due to the effects of hormones including leptin, insulin and inflammatory mediators. This causes an increase in afterload 6, 8 thus offsetting the advantage of reduced afterload of normal pregnancy affecting the CO further. This combination of volume and pressure overload leads to systolic dysfunction. Furthermore the increase in heart rate of pregnancy in line with elevated cardiac output will decrease the diastolic interval and time for myocardial perfusion causing diastolic dysfunction. Thus obese pregnant patients may present with a systolic, diastolic or both systolic and diastolic dysfunction of the left ventricle. Associated obstructive sleep apneoa (OSA) and pulmonary hypertension may lead to right ventricular failure. These changes are further compromised in the third trimester due to aortocaval compression thus reducing cardiac output and placental perfusion. The large abdominal panniculus in obesity will further add to the uterine and vascular compression. It is thus evident that obese parturient women pose an increase in risk for cardiovascular compromise. As obesity is considered a global health care problem especially in women, anaesthetists are increasingly faced with the care of this high risk group of patients.9However there is paucity of evidence to quantify this cardiovascular compromise on obese pregnant women and guide provision of best care.
Regional anaesthesia has been the preferred technique of anaesthesia, especially in obese pregnant patients. Induction of spinal anaesthesia will cause profound haemodynamic changes that represent the greatest hazard to the mother and the foetus. Evidence suggests these haemodynamic changes are common after spinal anaesthesia and results in hypotension causing unconsciousness, maternal nausea and vomiting, dizziness including deleterious effects on the foetus like neonatal acidaemia and lower APGAR score. However because of the changes in peripheral vascular resistance, changes in maternal arterial pressure do not necessarily reflect changes in maternal cardiac output. These changes in cardiac output and associated oxygen delivery pose the greatest risk to the foetus.
A recent review of cardiovascular alterations in the parturient undergoing caesarean delivery with neuraxial anaesthesia showed that induction of spinal anaesthesia will lead to decrease in CO by 10-35% as measured by various invasive techniques. Although the patho-physiology of pregnancy and obesity and echocardiography findings gives us an understanding that these patients are more prone for severe hypotension and cardiovascular compromise the extent of alteration of haemodynamic variables in obese pregnant patients during spinal anaesthesia has not been studied previously. Our primary aim therefore is to investigate the haemodynamic alterations in obese parturient during spinal anaesthesia and compare it with those in non-obese parturient.
Traditionally clinicians and researchers have used heart rate (HR)and BP as surrogate markers of cardiac output during spinal anaesthesia. Managing maternal BP was considered as safe optimization of foetal wellbeing. Recent publications have emphasized that keeping BP at baseline is not an optimal strategy and maintaining CO is superior in maintaining uterine blood flow. In addition the correlation of the foetal compromise in the form of umbilical artery pH and umbilical artery pulsatality index was better related to SV and CO than BP and heart rate. 19 Thus measurement of CO is considered a better approach than BP in optimising oxygen delivery to the foetus.
Although pulmonary artery catheterization is a gold standard for measuring cardiac output it is not desirable to use routinely because of its invasiveness, patient compliance and its potential complications. Minimally invasive CO monitors like LiDCO plus has been validated and successfully used for this purpose, but still require an arterial line and is complex for routine use.
LiDCOrapidV2(LiDCO Group plc, LiDCO Limited, United Kingdom), incorporates the CNAPTM (continuous noninvasive arterial pressure) module that derives CO, SV, and SVR from a continuous noninvasive arterial waveform and analysed by the PulseCOTM algorithm avoiding invasive blood pressure measurements. This study studies the clinical application of the LIDCOrapidV2 and compares the haemodynamic variables in obese and non-obese pregnant women having CS under spinal anaesthesia.
Study design
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (care provider)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| BMI less than 30 | Active comparator | Device: LiDCOrapidThe drop in cardiac output after spinal anaesthesia for LSCS at various intervals with LiDCORapid |
| BMI more than 40 | Experimental | Device: LiDCOrapidThe drop in cardiac output after spinal anaesthesia for LSCS at various intervals with LiDCORapid |
Who may qualify
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (2 listed)
- Pregnant patients with BMI of less than 30 undergoing elective CS.
- Obese pregnant patients with BMI of more than 35 undergoing elective CS
Key exclusion criteria (7 listed)
- Patients with other comorbidities like pre-eclampsia, eclampsia, essential hypertension, respiratory disease and compromised renal function.
- Patients on long-term medication.
- Patients having CS under epidural.
- Patients having general anaesthesia.
- Patients on antihypertensive medication.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| LiDCOrapidCardiac output will be non invasively monitored by using 2 cuffs on fingers. | Device | BMI less than 30, BMI more than 40 |
Primary outcome
Difference in the variation of cardiac output (CO) from baseline values between obese and non-obese parturients after spinal anaesthesia.
Time frame: 18 months
The change in cardiac output from baseline measured as milliliters/minute at predetermined intervals after spinal anaesthesia will be recorded in each group. The mean value of this change in each group will be compared for each recording and the difference in the change between the two groups will be reported.
1 secondary outcome
Mean difference in the amount of vasopressors infused in millilitres/hour between non-obese and obese pregnant women.
Time frame: 12 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Sep 2016.
- Individual participant dataSharing planned: No
Related trials for Low Cardiac Output
RecruitingObservational study
Validation of Continuous Transcutaneous Carbon Dioxide Monitoring in VA-ECMO Patients
Carbon Dioxide
RecruitingObservational study
Post-Induction Low Cardiac Output Syndrome in Coronary Artery Bypass Graft Surgery
Cardiac Output, Low, Coronary Arterial Disease
RecruitingObservational study
Performance of Carbon Dioxide (CO2)-Derived Parameters in Predicting Low Cardiac Output Syndrome
Low Cardiac Output Syndrome Bypass Children
Recruiting
Assessment of Cardiac Function and Anesthesia Depth in Patients Undergoing Cardiac Surgery
Heart Disease
Enrolling by invitation
LBBP + CSP Versus LBBP Alone for Cardiac Resynchronization Therapy
Heart Failure Low Output
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Manisha Kumar, FRCA principal investigator
NHS Grampian
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing LiDCOrapid in people with Low Cardiac Output, run by University of Aberdeen at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Sep 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Difference in the variation of cardiac output (CO) from baseline values between obese and non-obese parturients after spinal anaesthesia. (time frame: 18 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Sep 2016.